Hypertension and COVID-19: Updates from the era of vaccines and variants.
J Clin Transl Endocrinol
; 27: 100285, 2022 Mar.
Article
in English
| MEDLINE | ID: covidwho-1549902
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for coronavirus disease 2019 (COVID-19) has been a major cause of morbidity and mortality globally. Older age, and the presence of certain components of metabolic syndrome, including hypertension have been associated with increased risk for severe disease and death in COVID-19 patients. The role of antihypertensive agents in the pathogenesis of COVID-19 has been extensively studied since the onset of the pandemic. This review discusses the potential pathophysiologic interactions between hypertension and COVID-19 and provides an up-to-date information on the implications of newly emerging SARS-CoV-2 variants, and vaccines on patients with hypertension.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Topics:
Vaccines
/
Variants
Language:
English
Journal:
J Clin Transl Endocrinol
Year:
2022
Document Type:
Article
Affiliation country:
J.jcte.2021.100285
Similar
MEDLINE
...
LILACS
LIS